SUPPLEMENT

Q1 2020 — Reconciliation of Non-GAAP Financial Measures

Q1 2020PDF · 4 pages199 KB
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2020 	2019
Net Earnings, after tax- as reported 	$5,796 	$3,749
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,118 	1,130
Litigation expense 	120 	423
IPR&D 	- 	890
Restructuring related 	118 	90
Acquisition and Integration related ¹ 	(962) 	67
Unrealized (gains)/losses on securities 	327 	(158)
Medical Device Regulation 2 14 	-
Other 	- 	3
Tax Adjustments
Tax impact on special item adjustments 3 (267) 	(533)
Tax legislation and related impacts 	(110) 	-
Adjusted Net Earnings, after tax 	$6,154 	$5,661
Average shares outstanding (Diluted) 	2,671.0 	2,698.8
Adjusted net earnings per share (Diluted) 	$2.30 	$2.10
Operational adjusted net earnings per share (Diluted) 	$2.32
Notes:
1
2
3
First Quarter
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the
above pre-tax special items in arriving at adjusted earnings .
Acquisition and integration related costs for the first quarter of 2020 primarily includes a $983M Contingent
Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health
acquisition.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously
registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework,
and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021.
The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of
on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its
Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing
performance.

-- 1 of 4 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	9.2% 	8.7% 	(8.2)% 	3.3%
U.S. 	21.0% 	8.6% 	(6.8)% 	5.6%
International 	0.3% 	8.8% 	(9.4)% 	1.0%
WW Currency 	(2.1) 	(1.4) 	(1.3) 	(1.5)
U.S. 	- 	- 	- 	-
International 	(3.6) 	(3.2) 	(2.5) 	(3.0)
WW Operational 	11.3% 	10.1% 	(6.9)% 	4.8%
U.S. 	21.0% 	8.6% 	(6.8)% 	5.6%
International 	3.9% 	12.0% 	(6.9)% 	4.0%
Skin Health / Beauty
Dr. Ci Labo - Japan 	(0.4) 	(0.1)
U.S. 	0.0 	0.0
International 	(0.7) 	(0.1)
General Surgery
Advanced Sterilization Products 	2.1 	0.8
U.S. 	2.7 	0.9
International 	1.6 	0.6
Baby Care
Baby Center 	0.3 	0.0
U.S. 	0.8 	0.1
International 	0.0 	0.0
All Other Acquisitions and Divestitures 	(0.2) 	0.1 	(0.1) 	0.0
U.S. 	0.0 	0.1 	(0.2) 	0.0
International 	(0.3) 	0.0 	0.1 	0.0
WW Adjusted Operational 	11.0% 	10.2% 	(4.8)% 	5.6%
U.S. 	21.7% 	8.7% 	(4.3)% 	6.7%
International 	2.8% 	12.0% 	(5.3)% 	4.5%
Adjusted Operational Sales Growth
FIRST QUARTER 2020 ACTUAL vs. 2019 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 2 of 4 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019
Reported Income Before Tax by Segment 	$ 	770 	741 	3,834 	2,331 	2,025 	1,497 	(120) 	(147) 	6,509 	4,422
% to Sales 	21.2% 	22.3% 	34.4% 	22.8% 	34.1% 	23.2% 	-0.6% 	-0.7% 	31.5% 	22.1%
Intangible asset amortization 	100 	79 	771 	807 	247 	244 	- 	- 	1,118 	1,130
In-process research and development 	- 	- 	- 	890 	- 	- 	- 	- 	- 	890
Litigation expense, net 	- 	8 	93 	325 	27 	90 	- 	- 	120 	423
Unrealized loss/(gain) on securities 	1 	(4) 	314 	(143) 	12 	(11) 	- 	- 	327 	(158)
Restructuring related 	18 	7 	20 	25 	80 	58 	- 	- 	118 	90
Acquisition and integration related 	- 	- 	9 	39 	(971) 	28 	- 	- 	(962) 	67
Medical Device Regulation 	- 	- 	- 	- 	14 	- 	- 	- 	14 	-
Other 	- 	- 	- 	- 	- 	3 	- 	- 	- 	3
Adjusted Income Before Tax by Segment 	$ 	889 	831 	5,041 	4,274 	1,434 	1,909 	(120) 	(147) 	7,244 	6,867
% to Sales 	24.5% 	25.0% 	45.3% 	41.7% 	24.2% 	29.6% 	-0.6% 	-0.7% 	35.0% 	34.3%
*Estimated as of 04/14/2020.
Q1 YTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health 	Pharmaceutical 	Medical Devices 	Unallocated 	Worldwide Total

-- 3 of 4 --

First Quarter 	Acquistion and 	First Quarter
March 29, 2020
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Integration
related (1)
Medical Device
Regulation 	Other
March 29, 2020
Non-GAAP
Cost of products sold 	7,062	$ 	(1,118) 	(15) 	(14) 	5,915
Other (Income) / Expense 	(679) 	- 	(120) 	(45) 	962 	(327) 	(209)
In-process research and development 	- 	-
Restructuring 	58 	(58) 	-
Provision for taxes on income 	713 	146 	20 	21 	3 	75 	2 	110 	1,090
Net Earnings 	5,796 	972 	100 	97 	(965) 	252 	12 	(110) 	6,154
First Quarter 	Acquistion and 	First Quarter
March 31, 2019
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Integration
related (2)
Medical Device
Regulation 	Other
March 31, 2019
Non-GAAP
Cost of products sold 	6,615	$ 	(1,130) 	(23) 	5,462
Other (Income) / Expense 	(22) 	(423) 	(31) 	(67) 	158 	(3) 	(388)
In-process research and development 	890 	(890) 	-
Restructuring 	36 	(36) 	-
Provision for taxes on income 	673 	284 	81 	187 	15 	7 	(33) 	(8) 	1,206
Net Earnings 	3,749 	846 	342 	703 	75 	60 	(125) 	11 	5,661
(2) Includes $39M related to Actelion and $28M related to AMO (Pre-tax)
(1) Primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.
In-process
research and
development
Unrealized
(loss)/gain on
securities
Tax legislation
and related
impacts
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Unrealized
(loss)/gain on
securities
In-process
research and
development
Tax legislation
and related
impacts

-- 4 of 4 --